United States Immigration and Customs Enforcement is leveraging Palantir’s generative artificial intelligence tools to sort and summarize immigration enforcement tips from its public submission form, ...

We didn’t just track DX headlines in 2025 — we traveled to get the context behind them. Here’s what stood up to reality. By the end of 2025, the digital experience industry had moved past the most ...

Stack Exchange Inc., the company behind the leading developer resource Stack Overflow, today announced the public launch of its new AI Assist feature. The company says it provides users with access to ...

New features in WatchOS 26, plus some that have been in the watch since the beginning, can help you out all day. Jeff Carlson writes about mobile technology for CNET. He is also the author of dozens ...

Recursion, Roche, and its Genentech subsidiary have unveiled the latest product of their nearly four-year artificial intelligence (AI) drug discovery collaboration, a whole-genome map of specialized ...

Abstract: The generation of electrical energy from renewable energy sources (RESs) has increased over the past few decades as part of efforts to reduce humanity's environmental impact. However, their ...

Currently running commands with the '--recursive' flag groups actions in groups by dependency order and parallelizes each group one after another. This is nice because when used for builds it ensures ...

The Web Guide test uses Gemini to divide, curate, and explain your search results across AI-generated categories. The Web Guide test uses Gemini to divide, curate, and explain your search results ...

In a recent social media post, Peter Ray, senior director of medicinal chemistry at Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), drew attention to a new article in WIRED from Veronique Greenwood ...

So, you want to get good at LeetCode, especially using Java? It’s a common goal for a lot of us trying to land those tech jobs. This guide is all about helping you get there. We’ll go over how to ...

Recursion's AI-enabled drug discovery platform continues to evolve, but this is yet to translate into meaningful clinical success. The recent cull of programs has further undermined investor ...